Cardiorenal Anemia Syndrome as a Prognosticator for Death in Heart Failure

被引:36
|
作者
Lu, Ken J. [1 ,2 ,3 ]
Kearney, Leighton G. [1 ,2 ,3 ]
Hare, David L. [1 ,2 ,3 ]
Ord, Michelle [1 ,2 ,3 ]
Toia, Deidre [1 ,2 ,3 ]
Jones, Elizabeth [1 ,2 ,3 ]
Burrell, Louise M. [1 ,2 ,3 ]
Srivastava, Piyush M. [1 ,2 ,3 ]
机构
[1] Univ Melbourne, Dept Med, Melbourne, Vic 3010, Australia
[2] Austin Hlth, Melbourne, Vic, Australia
[3] Austin Hlth, Dept Cardiol, Melbourne, Vic, Australia
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2013年 / 111卷 / 08期
基金
英国医学研究理事会;
关键词
CHRONIC KIDNEY-DISEASE; CARDIAC-HYPERTROPHY; RISK-FACTORS; PREVALENCE; IRON; ERYTHROPOIETIN; OUTCOMES;
D O I
10.1016/j.amjcard.2012.12.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anemia and chronic kidney disease are common in patients with heart failure (HF) and are associated with adverse outcomes. We analyzed the effect of cardiorenal anemia (CRA) syndrome, defined as anemia (hemoglobin <130 g/L for men, <120 g/L for women) and stage 3 or greater chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m(2)), in outpatients with HF. Consecutive patients with HF were prospectively enrolled from 2000 to 2005 (n = 748). The baseline clinical characteristics, pathology test results, and medication use were compared between those with and without CRA syndrome. The primary end point was all-cause mortality. The mean follow-up was 2.5 +/- 1.6 years, with a left ventricular ejection fraction <45% present in 70% of patients. Angiotensin-converting enzyme inhibitors, blockers, and spironolactone were used in 87%, 67%, and 37%, respectively. CRA syndrome was present in 224 patients (30%). These patients had greater all-cause mortality (51% vs 26%, p <0.001), older age (mean 77 +/- 8 vs 67 +/- 14 years, p <0.001), and greater rates of diabetes mellitus (35% vs 23%, p <0.001) and ischemic heart disease (50% vs 35%, p <0.001). The independent predictors of mortality were CRA syndrome (hazard ratio 2.0, 95% confidence interval 1.4 to 2.8, p <0.001), left ventricular systolic dysfunction per grade (hazard ratio 1.5, 95% confidence interval 1.3 to 1.8, p <0.001), the absence of a beta blocker (hazard ratio 1.6, 95% confidence interval 1.1 to 2.2, p = 0.005), New York Heart Association class per class (hazard ratio 1.5, 95% confidence interval 1.2 to 1.9, p <0.01), and age per decade (hazard ratio 1.6, 95% confidence interval 1.4 to 2.0, p <0.001). In conclusion, CRA syndrome was common in patients with HF and was an independent predictor of all-cause mortality. Consideration should be given to identifying CRA syndrome and modifying reversible factors. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1187-1191)
引用
收藏
页码:1187 / 1191
页数:5
相关论文
共 50 条
  • [21] Cardiorenal Syndrome and Death Risk in Heart Failure or CKD Patients: An Urgent Call for Action
    Santos Araujo, Carla Alexandra R.
    Mendonca, Luis C.
    Seabra, Daniel
    Bernardo, Filipa
    Pardal, Marisa
    Couceiro, Joao
    Martinho, Hugo M.
    Dias, Daniel
    Dinis-Oliveira, Ricardo J.
    Gavina, Cristina
    Gomes, Tiago Taveira
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 225 - 225
  • [22] The Cardiorenal Syndrome in Heart Failure: An Evolving Paradigm
    Kshatriya, Shilpa
    Kozman, Hani
    Siddiqui, Danish
    Bhatta, Luna
    Liu, Kan
    Salah, Ali
    Ford, Timothy
    Michiel, Robert
    Villarreal, Daniel
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2010, 340 (01): : 33 - 37
  • [23] Management of the Cardiorenal Syndrome in Acute Heart Failure
    Valentina Lazzarini
    G. Michael Felker
    Current Treatment Options in Cardiovascular Medicine, 2012, 14 (4) : 342 - 355
  • [24] Anemia of cardiorenal syndrome
    McCullough, Peter A.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 35 - 45
  • [25] Cardiorenal syndrome in acute decompensated heart failure
    Aronson, Doron
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (02) : 177 - 189
  • [26] Cardiorenal Syndrome in Acute Decompensated Heart Failure
    Sarraf, Mohammad
    Masoumi, Amirali
    Schrier, Robert W.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (12): : 2013 - 2026
  • [27] Cardiorenal Anemia Syndrome and Survival among Heart Failure Patients in Tanzania: A Prospective Cohort Study
    Pallangyo, Pedro
    Fredrick, Francis
    Bhalia, Smita
    Nicholaus, Paulina
    Kisenge, Peter
    Mtinangi, Benjamin
    Janabi, Mohamed
    Humphrey, Stephen
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [28] Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?
    Pagourelias, Efstathios D.
    Koumaras, Charalambos
    Kakafika, Anna I.
    Tziomalos, Konstantinos
    Zorou, Paraskevi G.
    Athyros, Vasilios G.
    Karagiannis, Asterios
    ANGIOLOGY, 2009, 60 (01) : 74 - 81
  • [29] Advanced Heart Failure Therapies and Cardiorenal Syndrome
    Cowger, Jennifer A.
    Radjef, Ryhm
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (05) : 443 - 453
  • [30] Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome
    Bart, Bradley A.
    Goldsmith, Steven R.
    Lee, Kerry L.
    Givertz, Michael M.
    O'Connor, Christopher M.
    Bull, David A.
    Redfield, Margaret M.
    Deswal, Anita
    Rouleau, Jean L.
    LeWinter, Martin M.
    Ofili, Elizabeth O.
    Stevenson, Lynne W.
    Semigran, Marc J.
    Felker, G. Michael
    Chen, Horng H.
    Hernandez, Adrian F.
    Anstrom, Kevin J.
    McNulty, Steven E.
    Velazquez, Eric J.
    Ibarra, Jenny C.
    Mascette, Alice M.
    Braunwald, Eugene
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (24): : 2296 - 2304